The mystery of why prostate cancers become resistant to hormone therapy may partly lie in their ability to manufacture and stockpile cholesterol, the raw material for producing testosterone locally. This finding could reshape how oncologists approach advanced prostate cancer treatment by targeting metabolic vulnerabilities alongside traditional hormone blockade.
Researchers using DU145 prostate cancer cells discovered that fibroblast growth factor receptor 1 (FGFR1) acts as a master regulator of cellular cholesterol accumulation. When FGFR1 was eliminated from cancer cells, both cholesterol uptake through LDL receptors and internal cholesterol production dropped significantly. The mechanism involves FGFR1 activating SREBP2, a protein that controls cholesterol metabolism, through ERK-dependent phosphorylation pathways. This activation increases LDLR expression and enzymes necessary for cholesterol synthesis.
This discovery provides crucial mechanistic insight into castration-resistant prostate cancer development. Most prostate cancers initially respond to androgen deprivation therapy but typically progress within one to three years as tumors develop alternative testosterone sources. The ability to concentrate cholesterol appears central to this resistance, as cholesterol serves as the precursor for steroidogenesis—the cancer's backup plan for hormone production. While FGFR1 was already known to promote prostate cancer progression, its role in metabolic reprogramming represents a potentially targetable vulnerability. However, this represents laboratory findings in a single cell line, requiring validation across diverse prostate cancer types and patient samples. The therapeutic implications remain promising but preliminary, particularly given the complexity of metabolic networks in actual tumor environments versus simplified cell culture systems.